Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis

Cancer Research

Volumn 63, Issue 1, 2003, Pages 93-99

  Wittmann, Sylvie ^a   Bali, Purva ^a   Donapaty, Sreenivasa ^a   Nimmanapalli, Ramadevi ^a   Guo, Fei ^a   Yamaguchi, Hirohito ^a   Huang, Mei ^a   Jove, Richard ^a   Wang, Hong Gang ^a   Bhalla, Kapil ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYTOCHROME C; DOCETAXEL; EPOTHILONE B; FLAVOPIRIDOL; N ACETYLLEUCYLLEUCYLNORLEUCINAL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN; PROTEIN BAX; PROTEIN BCL XL; PROTEIN MCL 1; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN LOCALIZATION;

EID: 20244362748     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Senderowicz, A., and Sausville, E. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-385, 2000.
2. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schylze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
3. 1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999.
4. Worland, P. J., Daur, G., Stetler-Stevenson, M., Sebers, S., Sartor, O., and Sausville, E. A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol., 46: 1831-1840, 1993.
5. Senderowicz, A. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene, 19: 6600-6606. 2000.
6. Byrd, J. C., Shinn, C., Waselenko, K. J., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Fllinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, 92: 3804-3816, 1998.
7. Pepper, C., Thomas, A., Hoy, T., Fegan, C., and Bentley, P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br. J. Haematol., 114: 70-77, 2001.
8. Semenov, I., Akyuz, C., Roginskaya, V., Chauhan, D., and Corey, S. J. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk. Res., 26: 271-280, 2002.
9. Kitada, S., Zapata, J. M., Andreef, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000.
10. Li, Y., Bhuiyan, M., Alhasan, S., Senderowicz, A. M., and Sarkar, F. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin. Cancer Res., 5: 223-229, 2000.
11. Deveraux, Q. L., and Reed, J. C. IAP family of proteins: suppressors of apoptosis. Genes Dev., 13: 239-252. 1999
12. Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., Zhou, Q., Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J., 17: 2215-2223, 1998.
13. Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., and Altieri, D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (Lond.), 396: 580-584, 1998.
14. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T., and Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res., 58: 5315-5320, 1998.
15. Chen, J., Wu, W., Tahir, S. K., Kroeger, P. E., Rosenberg, S. H., Cowsert, L. M., Bennett, F., Krajewski, S., Krajewska, M., Welsh, K., Reed, J. C., and Ng, S. C. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia, 2: 235-241, 2000.
16. Sasaki, H., Sheng, Y., Kotsuji, F., and Tsang, B. K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res., 60: 5659-5666, 2000.
17. Olie, R. A., Simoes-Wust, A. P., Baumann, B., Leech, S. H., Fabbro, D., Stahel, R. A., and Zangemeister-Wittke, U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res., 60: 2805-2809, 2000.
18. Lam, L., Pickeral, O., Peng, A., Rosenwald, A., Hurt, E., Gilmane, J., Averett, L., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L., Harris, L., Harris, E., Mikovits, J., Monks, A., Hollingshead, M., Sausville, E., and Staudt, L. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol., 2: 0041.1-0041.11, 2001.
19. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., and Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem., 275: 28345-28348, 2000.
20. Price, D. H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol., 20: 2629-2634, 2000.
21. Bible, K. C., Bible, R. H., Jr., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y. P., Hajdu, E., and Kaufmann, S. H. Flavopiridol binds to duplex DNA. Cancer Res., 60: 2419-2428, 2000.
22. Winer, E., Morrow, M., Osborne, C. K., and Harris, J. Malignant tumors of the breast. In: V. T. Devita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, 6th ed., pp. 1651-1716. Philadelphia: Lippincott-Raven Publishers, 2000.
23. Burstein, H., Bunnell, C., and Winer, E. New cytotoxic agents and schedules for advanced breast cancer. Semin. Oncol., 28: 344-358, 2001.
24. Dumontet, C., and Sikic, B. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol., 17: 1061-1070, 1999.
25. Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E., and Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res., 55: 2325-2333, 1995.
26. Ibrado, A. M., Kim, C. N., and Bhalla, K. Temporal relationship of CDKI activation and mitotic arrest to cytosolic accumulation of cytochrome c and caspase-3 activity during Taxol-induced apoptosis. Leukemia (Baltimore), 12: 1930-1936, 1998.
27. L overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human AML HL-60 cells. Cancer Res., 57: 1109-1115, 1997.
28. Lee, F. Y., Borzilleri, R., Fairchild, C. R., Kim, S. H., Long, B. H., Reventos-Suarez, C., Vite, G. D., Rose, W. C., and Kramer, R. A. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res., 7: 1429-1437, 2001.
29. Yamaguchi, H., Paranawithana, S. R., Lee, M. W., Huang, Z., Bhalla, K. N., and Wang, H. G. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res., 62: 466-471, 2002.
30. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
31. Motwani, M., Jung, C., Sirotnak, F. M., She, Y., Shah, M. A., Gonen, M., and Schwartz, G. K. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res., 7: 4209-4219, 2001.
32. Motwani, M., Delohery, T. M., and Schwartz, G. K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 5: 1876-1883, 1999.
33. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102: 33-42, 2000.
34. Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., and Jove, R. Induction of p21 WAF1/CIP1 and cyelin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene, 19: 5419-5427, 2000.
35. Ibrado, A. M., Huang, Y., Fang, G., and Bhalla, K. Bcl-xL overexpression inhibits Taxol-induced Yama protease activity and apoptosis. Cell Growth Differ., 7: 1087-1094, 1996.
36. Perkins, C. L., Fang, G., Kim, C. N., and Bhalla, K. N. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res., 60: 1645-1653, 2000.
37. Guo, F., Nimmanapalli, R., Paranawithana, S., Wittman, S., Griffin, D., Bali, P., O'Bryan, E., Fumero, C., Wang, H. G., and Bhalla, K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative (BMS 247550)- and Apo-2L/TRAIL-induced apoptosis. Blood, 99: 3419-3426, 2002.
38. Hegde, R., Srinivasula, S., Zhang, Z., Wassell, R., Mukattash, R., Cilenti, L., DuBois, G., Lazebnik, Y., Zervos, A., Fernandes-Alnemri, T., and Alnemri, E. S. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem., 277: 432-438, 2002.
39. Ramadevi, N., Perkins, C., Orlando, M., Nguyen, D., O'Bryan, E., and Bhalla, K. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res., 6: 766-770, 2001.
40. Ramadevi, N., O'Bryan, E., and Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin (17-AAG) lowers Bcr-Abl level and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res., 61: 1799-1804, 2001.
41. Wang, X. The expanding role of mitochondria in apoptosis. Genes Dev., 15: 2922-2933, 2001.
42. Yunmbam, M. K., Li, Q. Q., Mimnaugh, E. G., Kayastha, G. L., Yu, J. J., Jones, L. N., Neckers, L., and Reed, E. Effect of the proteasome inhibitor ALLaL on cisplatin sensitivity in human ovarian tumor cells. Int. J. Oncol., 19: 741-748, 2001.
43. Konig, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., and Gabrilove, J. L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood, 90: 4307-4312, 1997.
44. Achenbach, T. V., Muller, R., and Slater, E. P. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J. Biol. Chem., 275: 32089-32097, 2000.
45. Li, F., Ackermann, E. J., Bennett, C. F., Rothermel, A. L., Plescia, J., Tognin, S., Villa, A., Marchisio, P. C., and Altieri, D. C. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol., 1: 461-466, 1999.